| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000041648 |
| Receipt No. | R000047535 |
| Scientific Title | Effect of Chlorella pyrenoidosa on Defecation -A Randomized, Double-blind, Cross-over-Study- |
| Date of disclosure of the study information | 2020/09/02 |
| Last modified on | 2020/09/02 (Ver. 1) |
| Basic information | ||
| Public title | Effect of Chlorella pyrenoidosa on Defecation | |
| Acronym | Effect of Chlorella pyrenoidosa on Defecation | |
| Scientific Title | Effect of Chlorella pyrenoidosa on Defecation
-A Randomized, Double-blind, Cross-over-Study- |
|
| Scientific Title:Acronym | Effect of Chlorella pyrenoidosa on Defecation
-A Randomized, Double-blind, Cross-over-Study- |
|
| Region |
|
|
| Condition | ||
| Condition | Healthy adult woman | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effect of the Chlorella intake on bowel movement and on intestinal environment |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Defecation frequency |
| Key secondary outcomes | Fecal amount, Fecal metabolite,
Intestinal flora, Clinical blood test, serum folate |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Chlorella food | |
| Interventions/Control_2 | Placebo control food | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | (1)Healty woman who are 20 or more to less than 60 years old
(2)Healthy Japanese subjects who defecate three to five times per week (3) Subjects must be able to come to the designated facility on the scheduled date of the clinical test (4)Subjects who are explained about the clinical test, show understanding of the test procedures, and obtain written consent from themselves in advance |
|||
| Key exclusion criteria | (1) Subjects who are continuously receiving treatment with medicines
(2) Subjects who regularly takes food for specified health use, functional foods, health foods, etc. that may affect the test. (3) Subjects who are pregnant (including subjects who may be pregnant) or lactating. (4) Subjects who donate blood or collect 200 ml or more of whole blood from 4 weeks prior to the start of the clinical test. (5) Subjects who collect 400 ml or more of whole blood from 16 weeks prior to the start of the clinical test. (6) Subjects whose blood collection volume from the month 12 months prior to the start of the clinical test to the start of it, plus the total planned blood collection volume for the clinical test, exceeds 800 ml (7) Subjects currently participate as test subjects in another clinical test or have participated in the test within 4 weeks (8) Subjects with pain or bleeding during defecation (9) Subjects who underwent laparotomy within 6 months of the test (10) Subjects who took antibiotics within 6 months of the test (11) Subjects who drink too much alcohol and smoke excessively. (12) Subjects with extremely irregular eating habits, shift work or midnight shift (13) Subjects who plan to change their lifestyle substantially during the test period (14) Subjects who are chronically prone to diarrhea (15) Subjects who falls under any of the following (a) Subjects with heart, liver or kidney disease (including when it is a complication of another disease) (b) Subjects with a history of cardiovascular disease |
|||
| Target sample size | 40 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Sun Chlorella Corporation | ||||||
| Division name | Production&Development Department Research&Development Group | ||||||
| Zip code | 600-8177 | ||||||
| Address | 369 Osaka-cho, Karasuma-dori Gojo-sagaru, Shimogyo-ku, Kyoto 600-8177 Japan | ||||||
| TEL | 075-288-3010 | ||||||
| mfujishima@sunchlorella.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Sun Chlorella Corporation | ||||||
| Division name | Production&Development Department Research&Development Group | ||||||
| Zip code | 600-8177 | ||||||
| Address | 369 Osaka-cho, Karasuma-dori Gojo-sagaru, Shimogyo-ku, Kyoto 600-8177 Japan | ||||||
| TEL | 075-288-3010 | ||||||
| Homepage URL | |||||||
| mfujishima@sunchlorella.co.jp | |||||||
| Sponsor | |
| Institute | Sun Chlorella Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Sun Chlorella Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Chiyoda Paramedical Care Clinic, Metabologenomics, Inc. |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Chushin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | チヨダパラメディカルケアクリニック(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 40 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047535 |